-

Blackstone Strategic Partners Closes Seventh Real Estate Secondaries Fund at $1.9 Billion

NEW YORK--(BUSINESS WIRE)--Strategic Partners, Blackstone’s (NYSE:BX) secondary and fund solutions business, announced today the final close on $1.9 billion for Strategic Partners Real Estate VII L.P. and its related committed program vehicles (collectively, “SP Real Estate VII”).

Verdun Perry, Senior Managing Director and Global Head of Strategic Partners, said: “This fundraise reflects the strong relationships we have built with our limited partners over the past two decades. We continue to reinforce our position as one of the private market’s most comprehensive sources of liquidity, while maintaining our reputation as a trusted and preferred counterparty.”

Mark Burton, Senior Managing Director and Head of Strategic Partners Real Estate said: “We have one of the market’s largest real estate portfolios, spanning interests in over 4,500 assets held by over 420 underlying real estate funds. Our ability to partner with both investors seeking liquidity and general partners and operators seeking strategic portfolio solutions will allow us to put capital to work in a wide range of real estate opportunities globally.”

About Strategic Partners

Strategic Partners is a market leader in private fund investing. Since 2000, Strategic Partners has raised $50 billion dedicated to private equity, infrastructure and real estate secondary and fund investing. Strategic Partners is recognized as an innovative and market-leading investor, with broad transaction capabilities that reinforce its established reputation as a nimble and responsive investor. Strategic Partners has executed over 1,450 transactions that represent interests in over 4,000 underlying fund vehicles managed by nearly 1,400 financial sponsors.

About Blackstone

Blackstone is one of the world’s leading investment firms. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $538 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com. Follow Blackstone on Twitter @Blackstone.

Contacts

Kate Holderness
kate.holderness@blackstone.com
+1 917 318 6818

Blackstone

NYSE:BX

Release Versions

Contacts

Kate Holderness
kate.holderness@blackstone.com
+1 917 318 6818

More News From Blackstone

Blackstone Energy Transition Partners Announces Agreement to Acquire Majority Stake in Advanced Cooling Technologies

NEW YORK & LANCASTER, Pa.--(BUSINESS WIRE)--Blackstone (NYSE: BX) and Advanced Cooling Technologies, Inc. (“ACT”) announced today that funds managed by Blackstone Energy Transition Partners (“Blackstone”) have entered into a definitive agreement to acquire a majority stake in ACT, a leading U.S. manufacturer of highly-engineered thermal management and energy efficiency solutions. ACT's executive team will remain in place and continue as significant shareholders in the business. Founded in 2003...

Blackstone Energy Transition Partners Announces Completion of 694MW Magnolia Power Generating Station in Louisiana

NEW YORK & PLAQUEMINE, La.--(BUSINESS WIRE)--Blackstone (NYSE: BX) announced today that private equity funds managed by Blackstone Energy Transition Partners (“Blackstone”) have completed construction of the Magnolia Power Generating Station (“Magnolia Power”), a 694-megawatt greenfield combined cycle gas turbine (“CCGT”) power plant in Plaquemine, Louisiana. Today’s announcement marks the beginning of commercial operations at the plant. Blackstone, through its North American power platform, Ki...

Blackstone Life Sciences Announces a Co-Funding Agreement for Acute Myeloid Leukemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences (“BXLS”) today announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for acute myeloid leukemia (“AML”). AML is the most common type of acute leukemia in adults, yet continues to be extremely challenging to treat, with the lowest survival of all leukemia types. Johnson & Johnson and funds managed by BXLS will jointly finance...
Back to Newsroom